In accordance, we observed strikingly upregulated GLUT4 transcription upon treatment of IPAH-PAAFs with either pan-HDAC or HDAC1/2 selective inhibitors, which hints the prospect of modulating GLUT4 levels with HDAC inhibitors to counteract the hyperglycemia and insulin resistance mechanisms observed in patients with PAH37. This evidence concerns the gene HDAC9 and Hyperglycemia.